Update on CEL-SCI's Phase III clinical trial of Multikine

CEL-SCI Corporation (NYSE AMEX: CVM) today provided an update on its planned Phase III clinical trial of its cancer immunotherapy drug candidate Multikine^®. The Company, together with its development partners Teva Pharmaceutical Industries and Orient Europharma, has already selected 40 of the planned 50 global medical centers where the Multikine Phase III study will be conducted. In addition, all major vendors for the study have now been chosen. CEL-SCI expects to enroll the first patient in the study during the third quarter of 2010.

“We are eager to commence the pivotal study to validate Multikine as the standard of care for newly diagnosed head and neck cancer patients”

The trial is expected to be the largest head and neck cancer clinical study ever conducted, with more than 800 patients expected to be enrolled worldwide. It will also be the first Phase III study in the world in which cancer immunotherapy is given to treatment naïve patients - before surgery, radiation and/or chemotherapy. This is believed to be the best time to stimulate an anti-tumor immune response as the immune system is still competent.

"We are eager to commence the pivotal study to validate Multikine as the standard of care for newly diagnosed head and neck cancer patients," said Geert Kersten, CEL-SCI's Chief Executive Officer. "We look forward to confirming the promising results that Multikine has already demonstrated in earlier clinical trials. We have taken every step to both minimize risk and maximize our chances for success."

Mr. Kersten continued, "If the huge success of Dendreon's Provenge^® has defined the first generation of cancer immunotherapy, we expect our Multikine to define the second generation. Multikine is an off the shelf product making large commercial production possible, it contains both passive and active immunity and is given before any other cancer therapy, a time when cancer immunotherapy should be most successful."

In Phase II clinical trials Multikine was shown to be safe and well-tolerated, and to eliminate the tumor in 12% of the patients after only three weeks of treatment. This patient response preceded the commencement of the current treatment regimen which includes one or a combination of surgery, radiation and chemotherapy. Follow-up showed an improvement in the Multikine treated patients' overall survival by 33% at a median of three and a half years following surgery. The U.S. Food and Drug Administration (FDA) gave the go-ahead for a Phase III clinical trial and granted orphan drug status to Multikine in the neoadjuvant therapy of patients having squamous cell carcinoma (cancer) of the head and neck.